Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab combined with apatinib mesylate and standard chemotherapy in ALK-positive advanced non-small cell lung cancer after tyrosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• CARBOPLATIN (Carboplatin)
• Camrelizumab (camrelizumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Lung Neoplasms | Phase 2 | Status: UNKNOWN